CD8A and B-cell chronic lymphocytic leukemia: The ratio of T cells:malignant monoclonal B cells (MBC) has been described as an independent predictor of time-to-first treatment (TTFT) in early stage CLL, with higher CD4:MBC and CD8:MBC ratios predicting longer overall survival (OS) [8].